New Biomarkers to Revolutionize RA Treatment
Company Announcements

New Biomarkers to Revolutionize RA Treatment

Oxford BioDynamics (GB:OBD) has released an update.

Oxford BioDynamics partners with King’s College London to develop EpiSwitch biomarkers aiming to improve rheumatoid arthritis (RA) treatment strategies post-Abatacept therapy. The collaboration follows the APIPPRA trial, the largest RA prevention trial, which revealed the need for better patient stratification tools. This initiative promises to enhance the identification of individuals at high risk of RA and optimize their treatment outcomes.

For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskOxford BioDynamics Reports Shift in Major Holdings
TipRanks UK Auto-Generated NewsdeskOxford BioDynamics Reports Major Shareholding Change
TipRanks UK Auto-Generated NewsdeskOxford BioDynamics Shareholding Structure Shifts
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App